AR029469A1 - Compuesto de azaindol, compuesto de azaindol de utilidad como intermediario para preparar el anterior, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima - Google Patents
Compuesto de azaindol, compuesto de azaindol de utilidad como intermediario para preparar el anterior, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultimaInfo
- Publication number
- AR029469A1 AR029469A1 ARP010100742A ARP010100742A AR029469A1 AR 029469 A1 AR029469 A1 AR 029469A1 AR P010100742 A ARP010100742 A AR P010100742A AR P010100742 A ARP010100742 A AR P010100742A AR 029469 A1 AR029469 A1 AR 029469A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- compound
- prepare
- azaindol
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 16
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000000840 anti-viral effect Effects 0.000 abstract 2
- -1 azaindole compound Chemical class 0.000 abstract 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18400400P | 2000-02-22 | 2000-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029469A1 true AR029469A1 (es) | 2003-07-02 |
Family
ID=22675206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100742A AR029469A1 (es) | 2000-02-22 | 2001-02-19 | Compuesto de azaindol, compuesto de azaindol de utilidad como intermediario para preparar el anterior, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20020061892A1 (enExample) |
| EP (1) | EP1257276B1 (enExample) |
| JP (1) | JP3868814B2 (enExample) |
| KR (1) | KR100496574B1 (enExample) |
| CN (1) | CN1404392A (enExample) |
| AR (1) | AR029469A1 (enExample) |
| AT (1) | ATE314072T1 (enExample) |
| AU (2) | AU2001232895B2 (enExample) |
| BR (1) | BRPI0108485B1 (enExample) |
| CA (1) | CA2400700C (enExample) |
| CO (1) | CO5271657A1 (enExample) |
| CY (1) | CY1107460T1 (enExample) |
| DE (1) | DE60116260T2 (enExample) |
| DK (1) | DK1257276T3 (enExample) |
| EG (1) | EG24669A (enExample) |
| ES (1) | ES2254367T3 (enExample) |
| HU (1) | HU229992B1 (enExample) |
| IL (1) | IL150734A0 (enExample) |
| MX (1) | MXPA02008113A (enExample) |
| MY (1) | MY128458A (enExample) |
| NO (1) | NO323564B1 (enExample) |
| NZ (1) | NZ520317A (enExample) |
| PE (1) | PE20020786A1 (enExample) |
| PL (1) | PL357434A1 (enExample) |
| PT (1) | PT1257276E (enExample) |
| RU (1) | RU2259372C2 (enExample) |
| TR (1) | TR200201961T2 (enExample) |
| TW (1) | TWI293629B (enExample) |
| UY (1) | UY26593A1 (enExample) |
| WO (1) | WO2001062255A1 (enExample) |
| ZA (1) | ZA200206073B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030207910A1 (en) * | 2001-02-02 | 2003-11-06 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| HU229305B1 (en) * | 2001-02-02 | 2013-10-28 | Bristol Myers Squibb Co | Antiviral substituted azaindoleoxoacetic piperazine dervatives and compositions thereof |
| US6825201B2 (en) * | 2001-04-25 | 2004-11-30 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
| US20040162298A1 (en) * | 2002-02-23 | 2004-08-19 | Hsu-Tso Ho | Method of treating HIV infection by preventing interaction of CD4 and gp120 |
| US20040063744A1 (en) * | 2002-05-28 | 2004-04-01 | Tao Wang | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
| US20050075364A1 (en) * | 2003-07-01 | 2005-04-07 | Kap-Sun Yeung | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives |
| ES2527118T3 (es) | 2003-12-19 | 2015-01-20 | Plexxikon Inc. | Compuestos y procedimientos de desarrollo de moduladores de Ret |
| CN1953985B (zh) * | 2004-03-15 | 2010-06-09 | 布里斯托尔-迈尔斯斯奎布公司 | 哌嗪和取代的哌啶抗病毒药物的前药 |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| US20050252408A1 (en) * | 2004-05-17 | 2005-11-17 | Richardson H W | Particulate wood preservative and method for producing same |
| HRP20090034T3 (en) | 2004-06-09 | 2009-03-31 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| US20060100209A1 (en) * | 2004-11-09 | 2006-05-11 | Chong-Hui Gu | Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US20060100432A1 (en) * | 2004-11-09 | 2006-05-11 | Matiskella John D | Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione |
| US7183284B2 (en) * | 2004-12-29 | 2007-02-27 | Bristol-Myers Squibb Company | Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents |
| US7601715B2 (en) | 2005-06-22 | 2009-10-13 | Bristol-Myers Squibb Company | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein |
| CA2616189C (en) | 2005-07-22 | 2019-03-26 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| US7598380B2 (en) * | 2005-08-03 | 2009-10-06 | Bristol-Myers Squibb Company | Method of preparation of azaindole derivatives |
| US7396830B2 (en) * | 2005-10-04 | 2008-07-08 | Bristol-Myers Squibb Company | Piperazine amidines as antiviral agents |
| CA2629232A1 (en) * | 2005-11-18 | 2007-05-24 | F. Hoffmann-La Roche Ag | Azaindole-2-carboxamide derivatives |
| US7851476B2 (en) * | 2005-12-14 | 2010-12-14 | Bristol-Myers Squibb Company | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine |
| US7807671B2 (en) * | 2006-04-25 | 2010-10-05 | Bristol-Myers Squibb Company | Diketo-piperazine and piperidine derivatives as antiviral agents |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| CN101679358B (zh) * | 2007-06-18 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | 作为p2y12拮抗剂的吡咯衍生物 |
| AU2008276063B2 (en) | 2007-07-17 | 2013-11-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009011912A1 (en) * | 2007-07-18 | 2009-01-22 | Bristol-Myers Squibb Company | A composition for treating hiv comprising virus-like particles |
| AU2009210296B2 (en) | 2008-01-31 | 2013-11-14 | Sanofi | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| SI2323633T1 (sl) * | 2008-09-04 | 2012-07-31 | Bristol Myers Squibb Co | Stabilni farmacevtski sestavek za optimizirano razdeljevanje hiv pripetih inhibitorjev |
| JP5511942B2 (ja) | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| EP2496086B1 (en) | 2009-11-06 | 2017-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2012075235A1 (en) | 2010-12-02 | 2012-06-07 | Bristol-Myers Squibb Company | Alkyl amides as hiv attachment inhibitors |
| SI2672967T1 (sl) | 2011-02-07 | 2018-12-31 | Plexxikon Inc. | Spojine in postopki za kinazno modulacijo in indikacije zanjo |
| AR085279A1 (es) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico |
| EP2696937B1 (en) | 2011-04-12 | 2017-05-17 | VIIV Healthcare UK (No.5) Limited | Thioamide, amidoxime and amidrazone derivatives as hiv attachment inhibitors |
| EP2751119B1 (en) | 2011-08-29 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Fused bicyclic diamine derivatives as hiv attachment inhibitors |
| US8664213B2 (en) | 2011-08-29 | 2014-03-04 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as HIV attachment inhibitors |
| WO2013138436A1 (en) | 2012-03-14 | 2013-09-19 | Bristol-Myers Squibb Company | Cyclolic hydrazine derivatives as hiv attachment inhibitors |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| CN102746295B (zh) * | 2012-06-20 | 2014-10-15 | 上海阿达玛斯试剂有限公司 | 4位取代-7-氮杂吲哚的制备方法 |
| EP2895472B1 (en) | 2012-08-09 | 2016-11-23 | VIIV Healthcare UK (No.5) Limited | Tricyclic alkene derivatives as HIV attachment inhibitors |
| US9505752B2 (en) | 2012-08-09 | 2016-11-29 | Viiv Healthcare Uk (No. 5) Limited | Piperidine amide derivatives as HIV attachment inhibitors |
| CN109528749B (zh) * | 2017-09-22 | 2023-04-28 | 上海交通大学医学院附属瑞金医院 | 长链非编码rna-h19在制备治疗垂体瘤药物中的用途 |
| IL301739A (en) | 2020-10-05 | 2023-05-01 | Enliven Therapeutics Inc | 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases |
| CN118515629A (zh) * | 2020-11-24 | 2024-08-20 | 中国人民解放军海军军医大学 | 一类取代苯甲酰哌嗪类化合物及其应用 |
| CN115855899B (zh) * | 2022-11-24 | 2025-06-10 | 常熟理工学院 | 一种荧光探针检测二氧化硫衍生物的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE142621T1 (de) * | 1989-12-28 | 1996-09-15 | Upjohn Co | Diaromatische substituierte verbindungen gegen den aids-virus |
| US5424329A (en) * | 1993-08-18 | 1995-06-13 | Warner-Lambert Company | Indole-2-carboxamides as inhibitors of cell adhesion |
-
2001
- 2001-01-18 US US09/765,189 patent/US20020061892A1/en not_active Abandoned
- 2001-01-19 DK DK01904970T patent/DK1257276T3/da active
- 2001-01-19 BR BRPI0108485A patent/BRPI0108485B1/pt not_active IP Right Cessation
- 2001-01-19 TR TR2002/01961T patent/TR200201961T2/xx unknown
- 2001-01-19 NZ NZ520317A patent/NZ520317A/en not_active IP Right Cessation
- 2001-01-19 RU RU2002125494/04A patent/RU2259372C2/ru not_active IP Right Cessation
- 2001-01-19 PT PT01904970T patent/PT1257276E/pt unknown
- 2001-01-19 WO PCT/US2001/002009 patent/WO2001062255A1/en not_active Ceased
- 2001-01-19 IL IL15073401A patent/IL150734A0/xx unknown
- 2001-01-19 ES ES01904970T patent/ES2254367T3/es not_active Expired - Lifetime
- 2001-01-19 KR KR10-2002-7010888A patent/KR100496574B1/ko not_active Expired - Fee Related
- 2001-01-19 MX MXPA02008113A patent/MXPA02008113A/es active IP Right Grant
- 2001-01-19 DE DE60116260T patent/DE60116260T2/de not_active Expired - Lifetime
- 2001-01-19 JP JP2001561320A patent/JP3868814B2/ja not_active Expired - Fee Related
- 2001-01-19 CN CN01805504A patent/CN1404392A/zh active Pending
- 2001-01-19 AU AU2001232895A patent/AU2001232895B2/en not_active Ceased
- 2001-01-19 EP EP01904970A patent/EP1257276B1/en not_active Expired - Lifetime
- 2001-01-19 AU AU3289501A patent/AU3289501A/xx active Pending
- 2001-01-19 AT AT01904970T patent/ATE314072T1/de active
- 2001-01-19 CA CA2400700A patent/CA2400700C/en not_active Expired - Fee Related
- 2001-01-19 HU HU0301508A patent/HU229992B1/hu not_active IP Right Cessation
- 2001-01-19 PL PL01357434A patent/PL357434A1/xx not_active Application Discontinuation
- 2001-02-06 MY MYPI20010516A patent/MY128458A/en unknown
- 2001-02-07 TW TW090102639A patent/TWI293629B/zh not_active IP Right Cessation
- 2001-02-19 EG EG20010152A patent/EG24669A/xx active
- 2001-02-19 AR ARP010100742A patent/AR029469A1/es active IP Right Grant
- 2001-02-20 CO CO01013156A patent/CO5271657A1/es not_active Application Discontinuation
- 2001-02-21 UY UY26593A patent/UY26593A1/es not_active IP Right Cessation
- 2001-02-22 PE PE2001000190A patent/PE20020786A1/es not_active Application Discontinuation
-
2002
- 2002-07-30 ZA ZA200206073A patent/ZA200206073B/en unknown
- 2002-08-21 NO NO20023981A patent/NO323564B1/no not_active IP Right Cessation
-
2006
- 2006-03-27 CY CY20061100420T patent/CY1107460T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029469A1 (es) | Compuesto de azaindol, compuesto de azaindol de utilidad como intermediario para preparar el anterior, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima | |
| AR040402A1 (es) | Metodos y usos terapeuticos de sapogeninas y sus derivados | |
| AR036127A1 (es) | Composicion para administracion topica que comprende un inhibidor de interleucina 2 y un agente antimicrobiano y uso de estos ultimos para preparar dicha composicion | |
| DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
| AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
| AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
| PE20231847A1 (es) | Compuestos fosfolipidos y usos de los mismos | |
| AR087046A2 (es) | Compuestos derivados de 4-oxoquinolina | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| AR030432A1 (es) | Uso de derivados de quinazolina en la preparacion de un medicamento para ser usado en la inhibicion de la quinasa aurora2, compuestos relacionados, y composicion farmaceutica. | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
| AR008864A1 (es) | DERIVADOS DE DIAMINO-1,3,5-TRIAZINA SUSTITUIDOS, PROCEDIMIENTOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS, PROCEDIMIENTO PARA LA PREPARACION DE DICHAS COMPOSICIONES, EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE UN MEDICAMENTO UTIL PARA INFECCIONES DE HIV, E INTERMEDIARIO uTIL PARA PREPA | |
| AR035069A1 (es) | Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento | |
| BR0314761A (pt) | Composto de adenina e seu uso | |
| AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| AR035516A1 (es) | Sulfonamidas heterociclicas y el uso de las mismas para la preparacion de medicamentos que inhiben la produccion de amiloides beta | |
| SE9904508D0 (sv) | New compounds | |
| TW200745101A (en) | 9-Azabicyclo[3.3.1]nonane derivatives | |
| AR023966A1 (es) | Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion | |
| BRPI0310032B8 (pt) | derivados de benzoxazina, seus usos e seus processos de produção, e composição farmacêutica | |
| MX2022000598A (es) | Preparacion de compuestos antibacterianos. | |
| PE20230412A1 (es) | Compuestos para su uso en afecciones inflamatorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |